Resource Summary Report

Generated by dkNET on Aug 4, 2026

Brilliant Violet 605(TM) anti-human CD8

RRID:AB_2566513
Type: Antibody

Proper Citation

BioLegend Cat# 344742, RRID:AB_2566513

Antibody Information

URL: http://antibodyregistry.org/AB_2566513

Proper Citation: BioLegend Cat# 344742, RRID:AB_2566513

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2566513

Vendor: BioLegend

Catalog Number: 344742

Alternative Catalog Numbers: 344741

Record Creation Time: 20250820T035327+0000

Record Last Update: 20250820T172724+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD8.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Gramatica A, et al. (2025) EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes. Cell reports, 44(5), 115652.

Cimen Bozkus C, et al. (2025) T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome. iScience, 28(8), 113044.

Giovenzana A, et al. (2024) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity. iScience, 27(3), 109032.

Zhu M, et al. (2024) Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell reports, 43(4), 114065.

Li Y, et al. (2024) SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Science translational medicine, 16(731), eadk1599.

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell metabolism, 36(1), 176.

Bopp L, et al. (2024) Glutamine promotes human CD8+ T cells and counteracts imiquimod-induced T cell hyporesponsiveness. iScience, 27(5), 109767.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. Cell reports, 42(6), 112657.

Yan C, et al. (2023) Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. Cancer cell, 41(7), 1276.

Silver AB, et al. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell reports. Medicine, 4(11), 101289.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. Cell, 185(8), 1414.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. Cell reports, 39(2), 110650.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell reports, 41(3), 111478.

Glassman CR, et al. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell, 184(4), 983.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. Cell reports, 35(4), 109038.